vintriptol

Also Known As:

N-(L-tryptophan ethyl ester)-4-deacetylvinblastine-3-carboxamide; VTrpE; vintripol; vintrypol

Networked: 5 relevant articles (0 outcomes, 3 trials/studies)

1.	Neoplasms (Cancer) 01/01/1991 - "In this phase I study, 47 patients with advanced cancer were exposed to escalating doses of vintriptol, starting at 6 mg/m2 and following a modified Fibonacci schedule. " 08/03/1990 - "The applicability of the assay was demonstrated in a pharmacokinetic study with eight cancer patients who received 45 or 50 mg/m2 vintriptol in a phase I study. " 02/14/1992 - "The assay was applied to the analysis of samples from cancer patients who had been treated with VtrpE in a phase I clinical study. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/1986 - "For VTrpE, a dose schedule of 30 mg/m2 per week may be recommended for phase II studies in non-small cell lung cancer."
3.	Ovarian Neoplasms (Ovarian Cancer) 12/01/1992 - "A comparative analysis was carried out of the anti-tumour activity of the four compounds as well as vintriptol in four human ovarian cancer xenografts different in histology, growth rate and chemosensitivity. "